共 39 条
[1]
Meade E.A., Smith W.L., deWitt D.L., Et al., Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other non-steroidal anti-inflammatory drugs, J. Biol. Chem., 268, pp. 6610-6614, (1993)
[2]
Chan C.C., Boyce S., Bridea C., Et al., Rofecoxib: A potent and orally active cyclooxygenase-2 inhibitor - Pharmalogical and biolchemical profiles, J. Pharmacol. Exp. Ther., 290, pp. 551-560, (1999)
[3]
Hawkey C.J., COX-2 inhibitors, Lancet, 353, pp. 307-314, (1999)
[4]
Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Et al., Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, N. Engl. J. Med., 343, pp. 1520-1528, (2000)
[5]
Barden J., Edwards J.E., McQuay H.J., Moore R.A., Single-dose rofecoxib for acute postoperative pain in adults: A quantitative systematic review, BMC Anesthesiol., 2, 1, (2002)
[6]
Ormrod D., Wellington K., Wagstaff A.J., Valdecoxib, Drugs, 62, pp. 2059-2071, (2002)
[7]
Cheer S.M., Goa K.L., Parecoxib (parecoxib sodium), Drugs, 61, pp. 1133-1141, (2001)
[8]
Talley J.J., Brown D.L., Carter J.S., 4-[5-Methyl-3-phenyl-lisoxazol-4-yl]-benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2, J. Med. Chem., 9, pp. 775-777, (2000)
[9]
Tramer M.R., Williams J.E., Carroll D., Wiffen P.J., Moore R.A., McQuay H.J., Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: A qualitative systematic review, Acta Anaesthesiol. Scandinavica, 42, pp. 71-79, (1998)
[10]
Moore R.A., Gavaghan D., Tramer M.R., Collins S.L., McQuay H.J., Size is everything - Large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects, Pain, 78, pp. 209-216, (1998)